PF-Atlas › Clinical Trials › NCT03485378

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

Stereotactic Ablative Radiotherapy · Not specified

Registry ID
NCT03485378
Phase
Not specified
Status
Active, not recruiting
Drug / intervention
Stereotactic Ablative Radiotherapy
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Start
2018-09-20
Enrollment
39
Locations
6

About this trial

This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.

View NCT03485378 on ClinicalTrials.gov →

Explore related

All Stereotactic Ablative Radiotherapy trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03485378 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.